The letter is in regards to certain disclosures made by the company on the ongoing USFDA audit of company’s Unit-1 and observations made by the USFDA between the period 2019 to 2022, Aurobindo Pharma Ltd (APL) said in a regulatory filing.
Copyright © 2024 | WordPress Theme by MH Themes